{"id":"W3012421263","doi":"10.1016/j.jval.2017.08.248","title":"Economic Evaluation of Nivolumab (NIVO) Plus Ipilimumab (IPI) Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada","year":2017,"lang":"en","type":"article","venue":"Value in Health","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Bristol-Myers Squibb (Canada)","funders":"","keywords":"Ipilimumab; Nivolumab; Medicine; Pembrolizumab; Internal medicine; Oncology; Discontinuation; Clinical trial; Population; Cost effectiveness; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003361382,0.0005127083,0.001062424,0.001009607,0.001140585,0.002468604,0.0009121708,0.0007072564,0.002132014],"category_scores_gemma":[0.01295257,0.0002633149,0.001945962,0.00193256,0.0007982141,0.0004759498,0.0007280022,0.001470642,0.00006242458],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.09564012,"about_ca_system_score_gemma":0.07232799,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.9442881,"about_ca_topic_score_gemma":0.9566864,"domain_scores_codex":[0.9970673,0.001342203,0.0001531014,0.00013682,0.0007191114,0.0005814851],"domain_scores_gemma":[0.9945003,0.001643969,0.0006867907,0.00007563355,0.001457758,0.001635594],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"not_applicable","study_design_scores_codex":[0.1327496,0.005029206,0.3037479,0.00788248,0.01607084,0.001244658,0.0007398936,0.2409013,0.002562446,0.01365392,0.03385489,0.2415629],"study_design_scores_gemma":[0.03214896,0.01692238,0.5649497,0.00449665,0.01921466,0.001028003,0.003324087,0.3147618,0.002160888,0.004076602,0.03642519,0.0004912369],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9492599,0.02324077,0.0006057966,0.007696414,0.0002150977,0.0008714927,0.006768066,0.00002535533,0.01131705],"genre_scores_gemma":[0.9951307,0.002492618,0.0003900223,0.0002605717,0.00002757468,0.0000641919,0.0009306564,0.000004764733,0.0006989398],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09564012,"threshold_uncertainty_score":0.6939209,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2610472587405355,"score_gpt":0.4041042178493367,"score_spread":0.1430569591088012,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}